VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-17

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

NCT06072430

Septic Shock Sepsis Hypovolemia

RECRUITING PHASE3

A Trial of Vitamin B12 in Septic Shock

NCT03783091

Septic Shock

COMPLETED PHASE2

A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent

NCT05251181

Hypovolemic Shock

NOT_YET_RECRUITING PHASE3

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

NCT02508649

Septic Shock

TERMINATED PHASE2/PHASE3

Midodrine Use in Septic Shock

NCT03706053

Septic Shock

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock.

Randomization and blinding: This is an open label study, randomization and blinding are not applicable to this study. All patients entering this study will be treated with VBI-S.

Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.

Analysis Populations: \* Safety Analysis Set (SAF): all patients who have received any amount of VBI-S. \* Intent to treat (ITT) population: all patients who have received any amount of VBI-S

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock Sepsis Hypovolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Treatment with VBI-S

Group Type EXPERIMENTAL

VBI-S

Intervention Type DRUG

VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VBI-S

VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female at least 18 years of age
2. Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection or an elevated procalcitonin of ≥ 2 ng/ml.
3. Patient has a mean blood pressure \< 65 mmHg that is unresponsive to fluids currently available on the market.
4. Sequential Organ Failure Assessment (SOFA) score \>= 5.
5. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:

* Lactate \> 2 mmol/L
* Mottled skin
* Decreased capillary refill of nail beds or skin
* Fever \> 38.3˚C, or 101˚F
* Hypothermia \< 36˚C core temperature (\<96.8˚F)
* Heart rate \> 90
* Tachypnea
* Change in mental status
* Significant edema or positive fluid balance (\>20 mL/kg over 24 hours)
* Hyperglycemia (\>140 mg/dL) in someone without diabetes
* White blood cell count \>12,000 or less than 4,000, or with \>10% "bands" (immature
* forms)
* Elevated C-reactive protein in serum (according to your lab's cutoffs)
* Elevated procalcitonin in serum (≥ 2 ng/ml)
* Arterial hypoxemia (PaO2/FiO2 \< 300)
* Acute drop in urine output (\<0.5 ml/kg/hr for at least 2 hours despite fluid resuscitation, or about 30 ml/hour for a 70 kg person)
* Creatinine increase \> 0.5 mg/dL
* INR \> 1.5 or aPTT \> 60 seconds
* Absent bowel sounds (ileus)
* High bilirubin (total bilirubin \> 4 mg/dL

Exclusion Criteria

1. Patients with a ventricular assist device
2. Acute coronary syndrome
3. Pregnant
4. Bronchospasm
5. Mesenteric ischemia
6. Emergency surgery
7. Acute liver disease (Hepatitis B and C as examples)
8. Liver failure with a Model for End-Stage Liver Disease (MELD) score ≥ 19
9. Hematologic or coagulation disorders including thrombocytopenia (platelet count \<50,000) and associated with hemodynamically significant active bleeding.
10. Absolute neutrophil count of \< 1000 mm3
11. Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs for COVID-19 and or septic shock
12. Patients with a known allergy to soybeans or eggs
13. Patient is hypervolemic as assessed by CVP, ultrasound, Swan Ganz catheter, Flo-Trac, esophageal doppler, bioimpedance, ECHO, Partial carbon dioxide rebreathing (NICO), lithium dilution (LIDCO) or other method published in a peer reviewed journal

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No